Escitalopram versus other antidepressive agents for depression

Cochrane Database of Systematic Reviews

Volumn , Issue 2, 2009, Pages

  Cipriani, Andrea ^a   Santilli, Claudio ^b   Furukawa, Toshi A ^c   Signoretti, Alessandra ^a   Nakagawa, Atsuo ^d   McGuire, Hugh ^e   Churchill, Rachel ^f   Barbui, Corrado ^a  

^a UNIVERSITY OF VERONA   (Italy)

^b UNIVERSITY OF PERUGIA   (Italy)

^c NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^d KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e National Collaborating Centre for Women's and Children's Health   (United Kingdom)

^f UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; BENZODIAZEPINE; CITALOPRAM; DULOXETINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; MILNACIPRAN; MIRTAZAPINE; OXAZEPAM; PAROXETINE; PLACEBO; REBOXETINE; SERTRALINE; TEMAZEPAM; VENLAFAXINE; ZALEPLON; ZOLPIDEM; ZOPICLONE; ANTIDEPRESSANT AGENT; SEROTONIN UPTAKE INHIBITOR;

AGGRESSION; AGITATION; ANAPHYLAXIS; ANOREXIA; ANXIETY; ASTHENIA; AUTOMUTILATION; BRONCHITIS; CALCULATION; CLINICAL ASSESSMENT; CLINICAL TRIAL; COLON OBSTRUCTION; COMA; CONSTIPATION; COST EFFECTIVENESS ANALYSIS; DEHYDRATION; DEPRESSION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DROWSINESS; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG MARKETING; DRUG MEGADOSE; DRUG OVERDOSE; DRUG TOLERABILITY; DRUG TOXICITY; DRUG WITHDRAWAL; DYSPEPSIA; EJACULATION DISORDER; ENURESIS; ERECTILE DYSFUNCTION; EYE DISEASE; FATIGUE; FLATULENCE; FLU LIKE SYNDROME; GASTRITIS; HEART FAILURE; HEART PALPITATION; HOT FLUSH; HUMAN; HYPERTENSION; HYPOTENSION; IMPOTENCE; INDIGESTION; INSOMNIA; IRRITABILITY; LETHARGY; LIBIDO; LIVER DISEASE; LOW DRUG DOSE; MAJOR DEPRESSION; MICTURITION DISORDER; MUSCULOSKELETAL DISEASE; NAUSEA; NERVOUSNESS; NOSE CONGESTION; ORTHOSTATIC HYPERTENSION; ORTHOSTATIC HYPOTENSION; OUTCOME ASSESSMENT; PAIN; PANIC; PELVIC INFLAMMATORY DISEASE; PHARYNGITIS; REMISSION; REVIEW; RHINITIS; SAMPLE SIZE; SEDATION; SENSITIVITY ANALYSIS; SEXUAL DYSFUNCTION; SIDE EFFECT; SINGLE DRUG DOSE; SINUSITIS; SKIN DISEASE; SOMNOLENCE; SUICIDAL IDEATION; SUICIDE; SWEATING; TACHYCARDIA; TINNITUS; TOOTH PAIN; TRANSIENT ISCHEMIC ATTACK; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; TREMOR; TRISMUS; UPPER RESPIRATORY TRACT INFECTION; VERTIGO; VOMITING; WEIGHT GAIN; WEIGHT REDUCTION; XEROSTOMIA; YAWNING; DECREASED APPETITE; INJURY; MENTAL CONCENTRATION; TREATMENT OUTCOME; META ANALYSIS; RANDOMIZED CONTROLLED TRIAL;

ANTIDEPRESSIVE AGENTS; CITALOPRAM; DEPRESSION; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEROTONIN UPTAKE INHIBITORS;

EID: 67649634725     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD006532.pub2     Document Type: Review

References (99)

1. Alexopoulos G, Gordon J, Zhang D. A placebo-controlled trial of escitalopram and sertraline in the treatment of major depressive disorder. Poster presented at the Annual Meeting of the American College of Neuropsychopharmacology, December, 2004.
2. Baldwin S, Cooper J A, Huusom A K T, Hindmarch I. A double-blind, randomized, parallel-group, flexible-dose study to evaluate the tolerability, efficacy and effects of treatment discontinuation with escitalopram and paroxetine in patients withmajor depressive disorder. International Clinical Psychopharmacology 2006;21(3):159-169. (Pubitemid 43740307)
3. Bielski R J, Ventura D, Chung-Chi Chang. A double-blind comparison of escitalopramand venlafaxine extended release in the treatment of major depressive disorder. Journal of Clinical Psychiatry 2004;65 (9):1190-1196.
4. Boulenger J-P, Huusom A K T, Florea I, Baekdal T, Sarchiapone M. A comparative study of the efficacy of long-term treatment with escitalopram and paroxetine in severly depressed patients. Current Medical Research and Opinion 2006;22(7):1331-1341. (Pubitemid 44085585)
5. Burke WJ, Gergel I, Bose A. Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients. Journal of Clinical Psychiatry 2002;63(4):331-336. (Pubitemid 34456361)
6. www.gsk.com/research/clinical/clinicalreg.html.
7. www.gsk.com/research/clinical/clinicalreg.html.
8. Colonna L, Andersen HF, Reines EH. A randomized, double-blind, 24-week study of escitalopram (10 mg/day) versus citalopram (20 mg/day) in primary care patients with major depressive disorder. Current Medical Research and Opinion 2005;21(10):1659-1668. (Pubitemid 41505032)
9. Kasper S, de Swart H, Andersen H F. Escitalopram in the treatment of depressed elderly patients. American Journal of Geriatric Psychiatry 2005;13(10):884-891. (Pubitemid 46638677)
10. Kennedy SH, Anderson HF, Lam RW. A pooled analysis of selective serotonin reuptake inhibitors and venlafaxine. Poster presented at the American Psychiatric Association, May, 2005.
11. Khan A, Bose A, Alexopoulos G S, Gommoll C, Li D, Gandhi C. Double-blind comparison of escitalopramand duloxetine in the acute treatment of major depressive disorder. Clinical Drug Investigation 2007;27(7):481-492. (Pubitemid 46919700)
12. Lepola UM, Loft H, Reines EH. Escitalopram(10-20 mg/day) is effective and well tollerated in a placebo-controlled study in depression in primary care. International Clinical Psychopharmacology 2003;18 (4):211-217. (Pubitemid 36871872)
13. Mao PX, Tang YL, Jiang F, Shu L, Gu X, Li M, Qian M, Ma C, Mitchell PB, Cai ZJ. Escitalopram in major depressive disorder: a multicenter, randomized, double-blind, fixed-dose, parallel trial in a Chinese population. Depress Anxiety 2008;25(1):46-54. (Pubitemid 351213924)
14. Montgomery S A, Huusom A K T, Bothmer J. A randomised study comparing escitalopramwith venlafaxine XR in primary care patients with major depressive disorder. Neuropsychobiology 2004;50:57-64. (Pubitemid 38721171)
15. Moore N, Verdoux H, Fantino B. Prospective, multicentre, randomized, double-blind study of the efficacy of escitalopram versus citalopram in outpatient treatment of major depressive disorder. International Clinical Psychopharmacology 2005;20(3):131-137. (Pubitemid 40571510)
16. Nierenberg A A, Greist J H, Mallinckrodt C H, Prakash A, Sambunaris A, Tollefson G, Wohlreich M M. Duloxetine versus escitalopram and placebo in the treatment of patients with major depressive disorder: onset of antidepressant action, a non-inferiority study. Current Medical Research and Opinion 2007;23(2):401-416. (Pubitemid 46333388)
17. www.forestclinicaltrials.com. Flexible-dose comparison of the safety and efficacy of Lu 26-054 (escitalopram), citalopram, and placebo in the treatment of major depressive disorder.
18. www.forestclinicaltrials.com. Double-blind comparison of the effects of Lu 26-054 (escitalopram) and fluoxetine on sleep in depressed patients.
19. www.forestclinicaltrials.com. Fixed-dose comparison of escitalopram combination in adult patients with major depressive disorder.
20. Ventura D, Armstrong E P, Skrepnek GH, Erder MH. Escitalopram versus sertraline in the treatment of major depressive disorder: a randomized clinical trial. Current Medical Research and Opinion 2007; 23(2):245-250. (Pubitemid 46333371)
21. Wade A, Gembert K, Florea I. A comparative study of the efficacy of acute and continuation treatment with escitalopram versus duloxetine in patients with major depressive disorder. Current Medical Research and Opinion 2007;23(7):1605-1614. (Pubitemid 47122170)
22. Yevtushenko VY, Belous AI, Yevtushenko YG, Gusinin SE, Buzik OJ, Agibalova TV. [Efficacy and tolerability of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, prospective, randomized, double-blind, active-controlled study in adult outpatients]. Clin Ther 2007;29(11):2319-2332
23. Als-Nielsen B, Chen W, Gluud C, Kjaergard LL. Association of funding and conclusions in randomized drug trials: a reflection of treatment effect or adverse events?. JAMA 2003;290:921-928 (Pubitemid 37430464)
24. Altman DG, Bland JM. Detecting skewness from summary information. BMJ 1996;313:1200.
25. Anderson IM, Nutt DJ, Deakin JF. Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 1993 British Association for Psychopharmacology guidelines. Journal of Psychopharmacology 2000;14:3-20.
26. American Psychiatric Association. Diagnostical and Statistical Manual of Mental Disorders (DSM-III). 3rd Edition. Washington, DC: APA, 1980.
27. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-III-R). 3rd Edition. Washington, DC: American Psychiatric Association, 1987.
28. American Psychiatric Association. Diagnostical and Statistical Manual of Mental Disorders (DSM-IV). 4rd Edition. Washington, DC: American Psychiatric Association, 1994.
29. American Psychiatric Association. Practice guideline for the treatment of patients with major depressive disorder (revision). American Journal of Psychiatry 2000;147:1-45. (Pubitemid 30193855)
30. Barbui C, Hotopf M, Freemantle M, Boynton J, Churchill R, Eccles MP. Selective serotonin reuptake inhibitors versus tricyclic and heterocyclic antidepressants: comparison of drug adherence. Cochrane Database of Systematic Reviews 2000, Issue 1. [DOI: 10.1002/14651858.CD002791.pub2]
31. Barbui C, Cipriani A, Brambilla P, Hotopf M. "Wish bias" in antidepressants drug trials?. Journal of Clinical Pharmacology 2004;24: 126-130. (Pubitemid 38380835)
32. Bekelman JE, Li Y, Gross CP. Scope and impact of financial conflicts of interest in biomedical research: a systematic review. JAMA 2003; 289:454-465 (Pubitemid 36119966)
33. Bhandari M, Busse JW, Jackowski D, Montori VM, Schunemann H, Sprague S. Association between industry funding and statistically significant pro-industry findings in medical and surgical randomized trial. CMAJ 2004;170:477-480. (Pubitemid 38293642)
34. Bollini P, Pampallona S, Tibaldi G, Kupelnick B, Munizza C. Effectiveness od antidepressants. Meta-analysis of dose-effect relationships in randomised clinical trials. British Journal of Psychiatry 1999; 174:297-303. (Pubitemid 29179711)
35. Buchkowsky SS, Jewesson PJ. Industry sponsorship and authorship of clinical trials over 20 years. Annals of Pharmacotherapy 2004;38: 579-585 (Pubitemid 38352217)
36. Cipriani A, Brambilla P, Furukawa T, Geddes J, Gregis M, Hotopf M, Malvini L, Barbui C. Fluoxetine versus other types of pharmacotherapy for depression. Cochrane Database of Systematic Reviews 2005, Issue 4. [DOI: 10.1002/14651858.CD004185.pub2]
37. Cipriani A, Barbui C, Brambilla P, Furukawa TA, Hotopf M, Geddes JR. Are all antidepressants really the same? The case of fluoxetine: A systematic review. Journal of Clinical Psychiatry 2006;67:850-864 (Pubitemid 44049083)
38. Cipriani A, Signoretti A, Furukawa TA, Churchill R, Tomelleri S, Omori IM, McGuire HF and Barbui C for the Meta-Analysis of New Generation Antidepressants (MANGA) Study Group. Venlafaxine versus other anti-depressive agents for depression. Cochrane Database of Systematic Reviews 2007, Issue 2.
39. Cipriani A, Furukawa TA, Veronese A, Watanabe N, Churchill R, McGuire HF and Barbui C for the Meta-Analysis of New Generation Antidepressants (MANGA) Study Group. Paroxetine versus other anti-depressive agents for depression. Cochrane Database of Systematic Reviews 2007, Issue 2.
40. Ciuna A, Andretta M, Corbari L, Levi D, Mirandola M, Sorio A, Barbui C. Are we going to increase the use of antidepressants up to that of benzodiazepines?. European Journal of Clinical Pharmacology 2004;60:629-634 (Pubitemid 40064595)
41. de Abajo FJ, García-Rodríguez LA. Risk of upper gastrointestinal tract bleeding associated with selective serotonin reuptake inhibitors and venlafaxine therapy: interaction with nonsteroidal anti-inflammatory drugs and effect of acid-suppressing agents. Arch Gen Psychiatry 2008;65(7):795-803.
42. Djulbegovic B, Lacevic M, Cantor A, Fields KK, Bennett CL, Adams JR, Kuderer NM, Lyman GH. The uncertainty principle and industry-sponsored research. Lancet 2000;356:635-638
43. Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 2007;369(9557): 201-207 (Pubitemid 46111014)
44. Ellis P. Australian and New Zealand practice guidelines for the treatment of depression. Australian and New Zealand Journal of Psychiatry 2004;38:389-407. (Pubitemid 39029045)
45. Etminan M, Takkouche B, Isorna FC, Samii A. Risk of ischaemic stroke in people with migraine: systematic review and meta-analysis of observational studies. BMJ 2005;330(7482):63. (Pubitemid 40093174)
46. Furukawa TA, Guyatt GH, Griffith LE. Can we individualize the "number needed to treat"? An empirical study of summary effect measures in meta-analyses. International Journal of Epidemiology 2002;31:72-76
47. Furukawa TA, McGuire H, Barbui C. Meta-analysis of effects and side-effects of low dosage tricyclic antidepression in depression: systematic review. BMJ 2002;325:991-995 (Pubitemid 35305144)
48. Furukawa TA, Cipriani A, Barbui C, Brambilla P, Watanabe N. Imputing response rate from means and standard deviations in metaanalysis. International Clinical Psychopharmacology 2005;20:49-52. (Pubitemid 40105550)
49. Furukawa TA, Barbui C, Cipriani A, Brambilla P, Watanabe N. Imputing missing standard deviations in meta-analyses can provide accurate results. Journal of Clinical Epidemiology 2006;59:7-10. (Pubitemid 41797469)
50. Geddes JR, Freemantle N, Mason J, Eccles MP, Boynton J. SSRIs versus other antidepressants for depressive disorder. Cochrane Database of Systematic Reviews 2000, Issue 2. [DOI: 10.1002/14651858.CD001851.pub2]
51. Gourion D. Antidepressants and their onset of action: a major clinical, methodological and pronostical issue. Encephale 2008;34(1): 73-81.
52. Guaiana G, Barbui C, Hotopf M. Amitriptyline versus other types of pharmacotherapy for depression. Cochrane Database of Systematic Reviews 2003, Issue 2. [DOI: 10.1002/14651858.CD004186.pub2]
53. Guaiana G, Andretta M, Corbari L, Mirandola M, Sorio A, D'Avanzo B, Barbui C. Antidepressant drug consumption and public health indicators in Italy. Journal of Clinical Psychiatry 2005;66:750-755 (Pubitemid 40942422)
54. Guy W, Bonato RR. Manual for the ECDEU Assessment Battery 2. Chevy Chase, MD: National Institute of Mental Health, 1970.
55. Hamilton M. A rating scale for depression. Journal of Neurology, Neurosurgery and Psychiatry 1960;23:56-62.
56. Hansen RA, Gartlehner G, Lohr KN, Gaynes BN, Carey TS. Efficacy and safety of second-generation antidepressants in the treatment of major depressive disorder. Ann Intern Med 2005;143(6):415-426 (Pubitemid 41341413)
57. Hansen RA, Gartlehner G, Lohr KN, Gaynes BN, Carey TS. Efficacy and safety of second-generation of antidepressants in the treatment of major depressive disorder. Annals of Internal Medicine 2005;143: 415-426 (Pubitemid 41341413)
58. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-560
59. Higgins JP, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions. Chichester: John Wiley & Sons, Ltd, 2005.
60. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 [updated February 2008]. Available from www.cochrane-handbook.org. The Cochrane Collaboration, 2008.
61. Imperadore G, Cipriani A, Signoretti A, Furukawa TA, Watanabe N, Churchill R, McGuire HF and Barbui C for the Meta-Analysis of New Generation Antidepressants (MANGA) Study Group. Citalopram versus other anti-depressive agents for depression. Cochrane Database of Systematic Reviews 2007, Issue 2.
62. Khan A, Khan SR, Walens G, Kolts R, Giller EL. Frequency of positive studies among fixed and flexible dose antidepressant clinical trials: an analysis of the food and drug administration summary basis of approval reports. Neuropsychopharmacologiy 2003;28:552-557
63. Kumra S, Oberstar JV, Sikich L, Findling RL, McClellan JM, Vinogradov S, Charles Schulz S. Efficacy and tolerability of second-generation antipsychotics in children and adolescents with schizophrenia. Schizophr Bull 2008;34(1):60-71. (Pubitemid 350262286)
64. Kupfer DJ, Frank E. Placebo in clinical trials for depression: complexity and necessity. JAMA 2002;287:1853-1854 (Pubitemid 34303631)
65. Le Lay A, Despiegel N, François C, Duru G. Can discrete event simulation be of use in modelling major depression?. Cost Eff Resour Alloc 2006;4:19. (Pubitemid 46189389)
66. Lexchin J, Bero LA, Djulbegovic B, Clark O. Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ 2003;326:1167-1170 (Pubitemid 36649048)
67. Linde K, Berner MM, Kriston L. St John's wort formajor depression. Cochrane Database of Systematic Reviews 2008, Issue 4.[Art. No.: CD000448. DOI: 10.1002/14651858.CD000448.pub3]
68. Lu M, Ades T. Assessing evidence consistency in mixed treatment comparisons. Journal of The American Statistical Association 2006; 101:447-459
69. Luborsky L. Clinician's judgements of mental health. Archives of General Psychiatry 1962;7:407-417
70. Lumley S. Network meta-analysis for indirect treatment comparisons. Statistics in Medicine 2002;21:2313-2324
71. Malvini L, Cipriani A, Furukawa TA, McGuire H, Churchill R, Barbui C for the MANGA Study. Sertraline versus other antidepressive agents for depression. (Protocol). Cochrane Database of Systematic Reviews 2006, Issue 3. [DOI: 10.1002/14651858.CD006117]
72. Moncrieff J, Kirsch I. Efficacy of antidepressants in adults. BMJ 2005;331:155-157
73. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. British Journal of Psychiatry 1979;134:382-389 (Pubitemid 9136500)
74. Montgomery JH, Byerly M, Carmody T, Li B, Miller DR, Varghese F. An analysis of the effect of funding source in randomized clinical trials of second generation antipsychotics for the treatment of schizophrenia. Controlled Clinical Trials 2004;25:598-612. (Pubitemid 39592864)
75. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 1997;349(9064):1498- 1504
76. Nakagawa A, Watanabe N, Omori IM, Cipriani A, Barbui C, McGuire H, Churchill R and Furukawa TA for the MANGA study group. Milnacipran versus other anti-depressive agents for depression. Cochrane Database of Systematic Reviews 2007, Issue 2. [DOI: 10.1002/14651858.CD006529]
77. National Institute for Health and Clinical Excellence. Depression: management of depression in primary and secondary care (amended). London: National Institute for Health and Clinical Excellence, 2007.
78. Nose M, Cipriani A, Furukawa TA, Omori IM, Churchill R, McGuire HF and Barbui C for the Meta-Analysis of New Generation Antidepressants (MANGA) Study Group. Duloxetine versus other anti-depressive agents for depression. Cochrane Database of Systematic Reviews 2007, Issue 2.
79. Omori I, Watanabe N, Cipriani A, Barbui C, McGuire H, Churchill R, Furukawa TA for the MANGA Study. Fluvoxamine versus other anti-depressive agents for depression. (Protocol). Cochrane Database of Systematic Reviews 2006, Issue 3. [DOI: 10.1002/14651858.CD006114]
80. Oxman AD, Guyatt GH. A consumer's guide to subgroup analyses. Annals of Internal Medicine 1992;116:78-84.
81. Patel V, Araya R, Chatterjee S, Chisholm D, Cohen A, De Silva M, Hosman C, McGuire H, Rojas G, van Ommeren M. Treatment and prevention of mental disorders in low-income and middle-income countries. Lancet 2007;370(9591):991- 1005. (Pubitemid 47384829)
82. Perlis RH, Perlis CS, Wu Y, Hwang C, Joseph M, Nierenberg AA. Industry sponsorship and financial conflict interest the reporting of clinical trials in psychiatry. American Journal of Psychiatry 2005;162: 1957-1960 (Pubitemid 41428627)
83. Procyshyn RM, Chau A, Fortin P, Jenkins W. Prevalence and outcomes of pharmaceutical industry-sponsored clinical trials involving clozapine, risperidone, or olanzapine. Canadian Journal of Psychiatry - Revue Canadienne De Psychiatrie 2004;49:601-606 (Pubitemid 39388352)
84. Psaty BM, Lumley T, Furberg CD, Schellenbaum G, Pahor M, Alderman MH, Weiss NS. Health outcomes associated with various antihypertensive therapies used as first-line agents: a network metaanalysis. JAMA 2003;289(19):2534-2544 (Pubitemid 37430155)
85. Puech A, Montgomery SA, Prost JF, Solles A, Briley M. Milnacipran, a new serotonin and noradrenaline reuptake inhibitor: an overview of its antidepressant activity and clinical tolerability. International Clinical Psychoharmacology 1997;12:99-108. (Pubitemid 27286559)
86. Salanti G, Higgins JP, Ades A, Ioannidis JP. Evaluation of networks of randomized trials. Stat Methods Med Res 2008;17:279-301.
87. Schwartz RS, Curfman GD, Morrissey S, Drazen JM. Full Disclosure and the Funding of Biomedical Research. N Engl J Med 2008;358: 1850-1851
88. Smith D, Dempster C, Glanville J, Freemantle N, Anderson I. Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: ameta-analysis. British Journal of Psychiatry 2002;180:396-404. (Pubitemid 34499333)
89. Sobocki P, Ekman M, Ovanfors A, Khandker R, Jönsson B. The costutility of maintenance treatment with venlafaxine in patients with recurrent major depressive disorder. Int J Clin Pract 2008;62(4): 623-632 (Pubitemid 351348039)
90. Tarn DM, Paterniti DA, Heritage J, Hays RD, Kravitz RL, Wenger NS. Physician communication about the cost and acquisition of newly prescribed medications. Am J Manag Care 2006;12(11):657-664 (Pubitemid 44748392)
91. Ware JE, Snow KK, Kosinski M, Gandek B. SF-36 Health Survey Manual and Interpetation Guide. Boston, MA: New England Medical Centre, 1993.
92. Watanabe N, Barbui C, Churchill R, Cipriani A, Furukawa TA, McGuire HF, Omori I for the MANGA Study. Mirtazapine versus other anti-depressive agents for depression (Protocol). Cochrane Database of Systematic Reviews 2006, Issue 3. [DOI: 10.1002/14651858.CD006528]
93. World Health Organization. The Ninth Revision of the International Classification of Diseases and Related Health Problems (ICD-9). Geneva: World Health Organisation, 1978.
94. World Health Organization. The Tenth Revision of the International Classification of Diseases and Related Health Problems (ICD-10). Geneva: World Health Organisation, 1992.
95. WHOQOL Group. The World Health Organization quality of life assessment (WHOQOL): Development and general psychometric properties. Social Science and Medicine 1998;46:1569-1585
96. Williams JW Jr, Mulrow CD, Chiquette E, Noel PH, Aguilar C, Cornell J. A systematic review of newer pharmacoterapies for depression in adults: evidence report summary. Annals of Internal Medicine 2000;132:743-756 (Pubitemid 30244176)
97. Wing J. Measuring mental health outcomes: a perspective from the Royal College of Psychiatrists. Outcomes into Clinical Practice. London: BMJ publishing 1994.
98. Wood L, Egger M, Gluud LL, Schulz KF, Jüni P, Altman DG, Gluud C, Martin RM, Wood AJ, Sterne JA. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. BMJ 2008;336 (7644):601-605
99. Zimmerman M, Posternak MA, Chelminski I. Derivation of a definition of remission on Montgomery-Asberg depression rating scale corresponding to the definition of remission on the Hamilton rating scale for depression. Journal of Psychiatric Research 2004;38:577-582 (Pubitemid 39348889)